The chemotherapeutic drug methotrexate selects for antibiotic resistance

Jónína S. Guðmundsdóttir a,*, Elizabeth G.A. Fredheim a, Catharina I.M. Koumans b, Joachim Hegstad a, c, Po-Cheng Tang d, Dan I. Andersson d, Ørjan Samuelsen a, e, Pal J. Johnsen a, *

a Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway
b Institute of Biology, Leiden University, Leiden, Netherlands
c Research and Development Division, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway
d Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
e Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway

ARTICLE INFO

Article History:
Received 4 September 2021
Revised 27 October 2021
Accepted 25 November 2021
Available online xxx

Keywords:
Chemotherapeutic drugs
E. coli
Antibiotic resistance
Methotrexate
Resistance evolution

ABSTRACT

Background: Understanding drivers of antibiotic resistance evolution is fundamental for designing optimal treatment strategies and interventions to reduce the spread of antibiotic resistance. Various cytotoxic drugs used in cancer chemotherapy have antibacterial properties, but how bacterial populations are affected by these selective pressures is unknown. Here we test the hypothesis that the widely used cytotoxic drug methotrexate affects the evolution and selection of antibiotic resistance.

Methods: First, we determined methotrexate susceptibility (IC90) and selective abilities in a collection of Escherichia coli and Klebsiella pneumoniae strains with and without pre-existing trimethoprim resistance determinants. We constructed fluorescently labelled pairs of E. coli MG1655 differing only in trimethoprim resistance determinants and determined the minimum selective concentrations of methotrexate using flow-cytometry. We further used an experimental evolution approach to investigate the effects of methotrexate on de novo trimethoprim resistance evolution.

Findings: We show that methotrexate can select for acquired trimethoprim resistance determinants located on the chromosome or a plasmid. Additionally, methotrexate co-selects for genetically linked resistance determinants when present together with trimethoprim resistance on a multi-drug resistance plasmid. These selective effects occur at concentrations 40- to >320-fold below the methotrexate minimal inhibitory concentration.

Interpretation: Our results strongly suggest a selective role of methotrexate for virtually any antibiotic resistance determinant when present together with trimethoprim resistance on a multi-drug resistance plasmid. The presented results may have significant implications for patient groups strongly depending on effective antibiotic treatment.

Funding: PJ was supported by UiT The Arctic University of Norway and the Northern Norway Regional Health Authority (SFP1292/16/HNF1586–21) and JPI-EC-AMR (Project 271,176/H10). DIA was supported by the Swedish Research Council (grant 2017–01,527). The publication charges for this article have been funded by a grant from the publication fund of UiT The Arctic University of Norway.

© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

Global overuse and misuse of antimicrobial drugs in combination with dwindling discovery rates of new antimicrobials have led to the current antibiotic resistance crisis [1]. It is also increasingly clear that non-antibiotic natural and anthropogenic substances affect antibiotic resistance evolution in bacterial populations and exacerbates the problem. These include biocides, metals and non-antibiotic drugs that may either directly select for antibiotic resistance, play important roles as co-selective agents, influence horizontal gene transfer (HGT) or mutation rates, and potentiate the effect of low antibiotic concentrations [2–5]. To effectively launch global initiatives to reduce antibiotic resistance there is an urgent need to identify novel drivers of resistance evolution. Antibiotic resistance is a major risk factor for patients with impaired immunity, such as cancer patients, and often a patient’s survival depends on antibiotic treatment to reduce the risk for hospital-acquired infections during chemotherapy.

https://doi.org/10.1016/j.ebiom.2021.103742
2352-3964/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Several cytotoxic drugs used in cancer chemotherapy are known to both elevate bacterial mutation rates and have direct antimicrobial properties \[8,9\]. It has been proposed that cancer chemotherapy may drive de novo antibiotic resistance evolution through the same and/or similar resistance mechanisms as antibiotics is potentially of great concern for both cancer patients and the general society. This report represents a first step that will enable us to target drug combinations where resistance evolution is less likely to be an undesired side effect of cancer treatment.

Evidence before this study

We searched PubMed and Web of Science for the following search terms: Methotrexate + trimethoprim + resistant*; Cytostatic + resistant* + antibiotic*; Cytostatic + cross + resistant* + antibiotic; Chemotherapy + driving + resistant* + antibiotic*; drivers/driving + antimicro + resistant*; fecal + cancer + trimethoprim in May 2020. We searched DataCite, Google Dataset Search and BASE in August 2021. The existing literature shows that many cytotoxic drugs, including methotrexate, a widely used drug for treatment of cancer and inflammatory diseases inhibit bacterial growth. Many of those drugs are also known to share molecular targets with commonly used antibiotics (e.g. methotrexate and trimethoprim). Further, it is proposed that cytotoxic drugs may drive antibiotic resistance evolution due to microbiome alterations, overlapping intrinsic resistome, and SOS induced mutagenesis.

Added value of this study

To our knowledge, we show for the first time that methotrexate directly selects for acquired trimethoprim resistance determinants on the chromosome as well as on a clinical multi-drug resistance plasmid. These selective and co-selective effects occur at methotrexate concentration ranges expected to represent intestinal concentrations during clinical use. Thus, we provide new evidence on how a cytotoxic drug can affect the evolution, selection, and spread of acquired antibiotic resistance determinants.

Implications of all the available evidence

The current antibiotic resistance crisis can have serious consequences for cancer treatment since these patients display higher risk of bacterial infections and consequently depend on antibiotic treatment. The indications that drugs used in cancer chemotherapy may drive resistance evolution through the same and/or similar resistance mechanisms as antibiotics is potentially of great concern for both cancer patients and the general society. This report represents a first step that will enable us to target drug combinations where resistance evolution is less likely to be an undesired side effect of cancer treatment.

2. Methods

2.1. Bacterial strains and growth conditions

Bacterial strains used in this study are listed in Table S1. All incubations of liquid cultures were performed with orbital shaking (225 rpm) at 37 °C, unless otherwise specified. Overnight cultures were grown in Miller Difco Luria-Bertani (LB) broth/agar (Becton, Dickinson and Co.). We used cation adjusted Mueller-Hinton II Broth (MHIIB, Becton, Dickinson and Co.). We used cation adjusted Mueller-Hinton II Broth (MHIIB, Becton, Dickinson and Co.) for assays with drugs supplemented to the media. When appropriate, media were supplemented with: 100 mg/L ampicillin (Sigma-Aldrich), 12.5 mg/L chloramphenicol (Sigma-Aldrich), 7.5 mg/L tetracycline (Sigma-Aldrich), 100 mg/ml Teva/Ebetrex (MTX) (Pfamachemie B.V./Ebewe Pharma Ges.m.b.H Nfg.KG). Methotrexate (MTX) was used in the form of a hydroxide with homologies to each end of the IS\text{150} region on the E. coli chromosome, central in DNA synthesis [14]. TMP in combination with sulfamethoxazole is among the most frequently used antibiotics in the treatment of urinary tract infections and is recommended as first line treatment internationally [15]. Our main target organism in this study is Escherichia coli, the most common agent of nosocomial infections worldwide [16]. E. coli is known to display intrinsic resistance towards MTX through AcrAB-ToIC mediated efflux [17], however TMP is not a substrate for this efflux system.

Previous studies have focused on the abilities of MTX and other non-antibiotics to inhibit bacterial growth [2]. These approaches have provided valuable insights on the effects of non-antibiotics as modulators of the intestinal flora, but lacked the necessary resolution to detect more subtle selective effects on acquired antibiotic resistance determinants.

Here, we hypothesize that despite the demonstrated E. coli intrinsic MTX resistance [17], MTX can affect antibiotic resistance evolution in E. coli, due to the shared molecular target with TMP. We show that MTX selects for acquired bacterial TMP resistance (TMP\text{R}) and co-selects for other antibiotic resistance determinants when co-residing on a mobile genetic element. Exposure to a wide concentration range of MTX selects for mutations identical to those emerging during TMP selection in clinical isolates of E. coli. Moreover, we show that the minimum selective concentrations (MSCs) of MTX and positive selection for chromosomal and plasmid-mediated TMP\text{R} determinants occurs for concentrations 40- and >320-fold below the MTX minimum inhibitory concentrations (MICs), respectively.

A promoter-levansucrase-chloramphenicol resistance-promoter cassette (P\text{cp25-sacB-cat-P\text{p231101}}) was first constructed by amplifying the sacB-cat-P\text{p231101} cassette (GenBank: KM018298) by using primers with homologies to each end of the \text{insKJ} and partially \text{mokA} genes in the IS\text{150} region on the E. coli MG1655 chromosome (Table S2). The

2.2. Strain constructions

A promoter-levansucrase-chloramphenicol resistance-promoter cassette (P\text{cp25-sacB-cat-P\text{p231101}}) was first constructed by amplifying the sacB-cat-P\text{p231101} cassette (GenBank: KM018298) by using primers with homologies to each end of the \text{insKJ} and partially \text{mokA} genes in the IS\text{150} region on the E. coli MG1655 chromosome (Table S2). The
construct was introduced onto the chromosome by Red recombining [19,20] in a strain carrying the pSIM5 plasmid [21] with tetracycline as the antibiotic selection marker (pSIM5-ret, DA45134). Chloramphenicol resistance was used to select for the inserted construct.

Fluorescent protein encoding: bfp (cat-PJ23101-mtagBFP2, blue; [4]; GenBank: KM018299), yfp (cat-PJ23101-sYPFP2, yellow; [4]; GenBank: KM018300) were PCR amplified from previous strains [4]. PCR amplifications were carried out using Phusion High-Fidelity DNA Polymerase (Thermo Scientific). Reaction primers were designed with one of the 40 bp homology to the disrupted IS150 locus whilst the other retained the P<sub>CP25</sub> promoter (Table S2). Reaction products were purified using the Genejet Purification Kit (Thermo Scientific) and introduced onto the chromosome by Red recombination by counter-selection on sucrose agar medium. This resulted in [P<sub>CP25</sub>-sYPFP2] and [P<sub>CP25</sub>-mtagBFP2] constructs.

Dup-In methodology of the IS150 locus was carried out on all previous constructs [22] using the sacB-cat-P<sub>32101</sub> cassette (GenBank: KM018298) and chloramphenicol resistance as the antibiotic selection. P1vir lysates for both fluorescent markers were prepared and transduced into a common background (DA4201) by generalized transduction and segregation of Dup-Ins. Briefly, transduced colonies were picked from plates first with chloramphenicol resistance to transfer the Dup-In with the IS150 locus, then single colonies were patched on sucrose plates for loss of the sacB-cat-P<sub>32101</sub> Cassette but retaining of the IS150 locus. For screening of the final strains constructed and generation of templates for Sanger sequencing, DreamTaq PCR Master Mix (Thermo Scientific) was used.

The fluorescently tagged strains were further engineered to obtain TMP<sup>d</sup> derivatives. Two point mutations associated with folA (one in the folA gene, W30R, and the second 58 bp upstream of folA within the promoter region, C<sub>−</sub>T) were introduced onto the chromosome of the strains using a double MAGE cycle with the pPORTMAGE-1 plasmid (RRID:Addgene_72,677) as described by previously [23]. The pG06-VIM-1 [24], was transformed into the fluorescently tagged strains as well as Klebsiella pneumoniae using room temperature electroporation [25].

To verify the role of dfrA genes in both TMP<sup>d</sup> as well as methotrexate resistance (MTX<sup>d</sup>), both dfrA1 and dfrA12 were PCR amplified using Phusion High-Fidelity DNA Polymerase (New England BioLabs Inc., Table S2), purified using QiAquick PCR Purification Kit (QIAGEN), phosphorylated using T4 Polynucleotide Kinase (Thermo Scientific) and cloned using T4 DNA Ligase (Thermo Scientific) into the pBAD30 vector at the Smal site. Thus, gene expression was under a tightly inducible control by the P<sub>BAD</sub> promoter when in the presence of arabinose [26]. The purified ligation reactions were transformed into electro- competent DH5<sub>α</sub> cells with electroporation and clones carrying the vector-born dfrA genes isolated.

2.3. Susceptibility testing

Due to the bacteriostatic activities of MTX and a lack of a gold standard for MTX microbiological assays we define the MIC of MTX in this study as the 90% inhibitory concentration (IC<sub>90</sub>). This allows for a high resolution and has previously been used as a proxy for the MIC [27,28]. The IC<sub>90</sub> values for TMP and MTX were determined as described previously with minor changes [29]. Briefly, 96-well plates were incubated at 300 rpm when containing MTX and 700 rpm when containing TMP (3 mm stroke) for 18 h at 37 °C before the OD<sub>900</sub> was measured using an Epoch 2 Microplate Spectrophotometer (BioTek Instruments, Inc.)/VersaMax<sup>™</sup> ELISA Microplate (Molecular Devices<sup>®</sup>). Internal controls were included on all plates. Percent inhibition was calculated as previously described [30]. At least three biological replicates were used and the MIC was set as the most read (modal) value on a two-fold scale of replicates that met quality control standards. For characterization of TMP<sup>d</sup> mutants isolated from the MTX sub-MIC evolution, TMP MIC was determined by gradient diffusion strips following the manufacturer’s guidelines (Liofilchem). Measurements were done using two to four biological replicates, where the MIC was set as the most read (modal) value.

2.4. Growth rate measurements

Growth rates were determined using a Bioscreen C MBR reader (Oy Growth Curves Ab, Ltd). A minimum of five independent overnight cultures of each strain were diluted to ~5 × 10<sup>6</sup> CFU/mL in MHIIB containing MTX at concentrations ranging from 0 to 8 mg/mL. Two 300 μL aliquots of each dilution were transferred into sterile Honeycomb plates (Oy Growth Curves Ab, Ltd). The samples were grown at 37 °C with continuous shaking for 18 h and OD<sub>900</sub> values were measured every 4 min. The growth curves from the Bioscreen C measurements were analysed and growth rate calculations done using the statistical software R [31]. In short, the R package Bioscreen Analysis Tool BAT 2.1 [32] was used to calculate the doubling time of each well by fitting a straight line to the logarithmic phase (OD<sub>900</sub> values between 0.02 and 0.1). Relative growth rates were then calculated by dividing the mean doubling time of the reference strain grown without any drug present by the mean doubling time of the strain and condition being tested.

2.5. Competition experiments

Competition experiments were performed using the fluorescently tagged strain pairs, both for folA and pG06-VIM-1 mediated TMP<sup>d</sup>. A susceptible strain tagged with either yfp or bfp was mixed at 1:1 ratio with the constructed TMP<sup>d</sup> strains harbouring the disparate fluorescence marker to initiate a head-to-head competition, at different MTX concentrations. Six independent cultures (~5 × 10<sup>9</sup> CFU/mL) of each strain were used to start 12 competitions, i.e. six biological replicates for each unique arrangement in a dye-swap set-up. Every 24 h for three to four days the competing strains were passaged by a 1:1000 dilution into fresh medium and the mutant to wild type (wt) ratio measured by counting 10<sup>6</sup> cells using a fluorescence-activated cell sorter (BD FACs Aria III). For safety reasons, all cultures were washed in fresh drug-free MHII in order to remove MTX from the cultures before FACs analysis. Cells were pelleted at 5000 rcf at 4 °C for 5 min, MTX containing supernatant removed and cells resuspended in fresh MHII.

Selection coefficients were calculated according to the regression model s=[ln(R(t)/R(0))/t], as previously described [33], where R is the mutant to wt ratio and t is the time measured in generations of growth. The minimum selective concentration (MSC) is defined as the concentration where the selection coefficient equals zero (where the regression line crosses the x-axis) [34].

In a similar way, six individual cultures of a susceptible yfp strain was competed against the bfp resistant strains in 1:1, 1:10, 1:10<sup>2</sup>, 1:10<sup>3</sup> and 1:10<sup>4</sup> starting ratios of TMP<sup>d</sup>:TMP<sup>d</sup> strains at concentrations slightly above the estimated MSCs (400 μg/mL for folA mutant, 75 μg/mL for p06-VIM-1).

To assess the stability of the pG06-VIM-1 in the presence of MTX, three independent lineages of K56–75 harbouring the plasmid (MP05–31) were serially passaged for 50 generations (1:100-dilution) in 1 mL MHII batch cultures with 400 μg/mL MTX. The lineages were then plated on non-selective agar. One hundred colonies from each lineage was replica plated and reduced susceptibilities towards ampicillin, TMP, streptomycin and spectinomycin determined by patching on MHII agar supplemented with 100 μg/mL ampicillin, 25 μg/mL TMP, 40 μg/mL streptomycin or 40 μg/mL spectinomycin as well as MHII agar.

2.6. Selective plating on high concentrations of MTX

Single MTX resistant mutants of K56–2 (MP06–01) were selected at lethal MTX concentrations. Dense overnight cultures grown in
drug-free LB was concentrated 10 ×, and 100 µL spread on LB agar plates supplemented with 4, 8 and 16 mg/mL MTX. Mutants were picked after 48 to 96 h and purified on non-selective plates. Additionally, an overnight culture in LB containing MTX at the estimated MIC concentration was concentrated 10 × and 100 µL spread on LB agar plates with and without MTX 32 mg/mL. After 48 h incubation, mutants were purified on non-selective plates. The MTX and TMP MICs for all mutants isolated were determined as previously described by IC₅₀ testing [29] and the folA gene, its promoter area and the mrr gene sequenced with Sanger sequencing and analyzed using the CLC Main Workbench (QIAGEN).

2.7. Laboratory evolution at sub-MICs of MTX

To examine the effect of MTX on TMPR evolution, strain K56–2 (MP06–01) was serially passaged in liquid cultures with MTX supplemented at concentration slightly above the estimated MSC. Initially, 10 independent overnight cultures were started from independent colonies on separate agar plates from which ~10⁵ cells were used to start ten independent lineages in 1 mL MHIIb containing 400 µg/mL MTX (lineages 1–10). Every 12 h for 25 days, the lineages were serially passaged by 1000-fold dilution in 1 mL batch cultures, allowing for ~500 generations of growth. Every ~50 generations the populations were frozen down at -80°C. In parallel, three independent control lineages were simultaneously sampled for TMP resistance under the same experimental conditions except for MTX exposure (lineages 11–13). After ~500 generations of growth end-point populations were plated on MHII agar plates containing 32 mg/mL MTX. From lineages 1–10, 20 colonies were isolated from each and tested for TMPR with no increase in TMP resistance detected compared to the parental strain. The frozen populations were gently thawed on ice and diluted series plated on both MHII agar with TMP 4 µg/mL and without drug, and frequencies of TMP resistant mutants calculated. From each plate where mutants grew, up to five colonies were randomly isolated, their susceptibility towards TMP measured, and the folA gene and its promoter area sequenced with Sanger sequencing and analyzed using the CLC Main Workbench (QIAGEN). No MTXR or TMPR colonies were isolated from the lineages grown without drug (lineages 11–13).

2.8. Whole genome sequencing

To investigate the possibility of additional genetic changes during MTX selection, other than the TMPR determinants shown to be associated with reduced susceptibility towards MTX, five isolates from the lethal selection were chosen (MP18–13, MP18–17, MP18–20, MP18–26 and MP18–28) based on their different susceptibility profiles and subjected to whole genome sequencing (WGS). Bacteria were grown overnight and genomic DNA prepared using GenEluteTM Bacterial Genomic DNA Kit (Sigma-Aldrich) following the manufacturer’s instructions with slight adaptations. In brief, 1.5 mL of dense culture (OD₆₀₀: 0.8–1.0) was pelleted by centrifugation at 13000 rpm and supernatant removed. The pellet was resuspended in 200 µL of lysis solution (100 mg/mL) and incubated for 30 min at 37°C, before 20 µL of RNase A solution was added and incubated for 2 min at room temperature. Following, 20 µL of Proteinase K (20 mg/mL) and 200 µL of Lysis solution C were added to the mixture and incubated at 55°C for 10 min after being thoroughly vortexed. To each pre-assembled GenElute Miniprep Binding Column, 500 µL of the Column Preparation Solution were added, 200 µL of ethanol (95–100%) was then added to the lysate and thoroughly mixed before the lysate was carefully loaded onto the binding column, centrifuged at 13000 rpm for 1 min and then washed 2 × with 500 µL of Wash Solution. Genomic DNA was eluted in 100 µL of 10 mM Tris-base and purity and concentration determined using NanoDrop One (Thermo Scientific) and Qubit (Thermo Scientific) respectively. Next-generation sequencing libraries were prepared from the bacterial genomic DNA samples and sequenced on an Illumina NovaSeq with a 2 × 150 bp configuration (GENEWIZ). Average whole genome coverage per sample was approximately 700. Analysis of the fastq files obtained from Illumina sequencing was performed using an in-house bioinformatic pipeline (Table S3) to compare the mutant sequences to the previously published wt strain (available at NCBI, BioSample SAMN08095529). Where single-nucleotide polymorphisms (SNPs) were identified with a coverage below 100, the evidence was considered insufficient and the SNPs were removed from the analysis. Raw sequence reads were deposited under BioProject PRJNA677979.

2.9. Statistics

Means and standard deviations were estimated using the software R (version 4.1.0) and RStudio (version 1.4.1717).

2.10. Role of the funders

The funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.

3. Results

3.1. Methotrexate selects for pre-existing TMPR determinants

We initially determined the MICs of MTX in clinical [35] and laboratory strains of E. coli (Table S1). Initial experiments revealed variable, but high MTX MICs, ranging from 4 to 32 mg/mL in the different genetic backgrounds, with the exception of ~0.25 mg/mL for E. coli W3110 ΔTNRLoC (Tables S4-S5) [26]. This being consistent with previous reports demonstrating that E. coli displays intrinsic resistance towards MTX due to AcrAB-ToIC mediated efflux [2,17]. We also observed that the MTX MIC was dependent on the presence of TMPR determinants. All isolates with a functional TMPR determinant and increased TMP MIC showed consistently higher MTX MICs (~32 mg/mL) than TMP susceptible (TMPS) isolates (4–32 mg/mL), indicating possible co-selective abilities of the two drugs. This included strains of both E. coli as well as K. pneumoniae ATCC13883 harbouring the clinical multi-drug resistance (MDR) plasmid pG06-VIM-1. Strains of both species harbouring the plasmid displayed reduced susceptibility towards MTX as well as TMP (Table S4-S5).

Antibiotic resistance selection and co-selection have traditionally been assumed to occur between the MICs of susceptible and resistant isolates within a bacterial population (known as the selective window) [34]. However, several reports unequivocally show that antibiotic resistance selection and co-selection can occur at concentrations several hundredfold below the MIC of a susceptible isolate (known as sub-MIC) [4,34,37]. To test how sub-MICS of MTX affect bacterial fitness, we measured exponential growth rates for two pairs of clinical isogenic TMPR and TMPR E. coli across a wide MTX concentration span. One pair with TMPR located on the chromosome (one intragenic point mutation T→A (W30R) in the folA gene, and one in its promoter region (perm, C–T 58 base pairs (bp) upstream of the gene) (MP06–01) [29] and one pair with TMPR (dfrA) located on the MDR plasmid pG06-VIM-1 (MP05–31) [24]. TMPR strains displayed sharply declining growth rates between 1 and 2 mg/mL of MTX, whereas the TMPR strains remained unaffected (Figure S2, Table S6). These results suggest a selective benefit during MTX exposure for TMPR strains at concentrations below the observed MTX MIC of the TMPR clinical isolates. The same effect was observed in the nosocomial pathogen K. pneumoniae ATCC13883 where a dose response curve comparing the strain with and without pG06-VIM-1 shows a clear difference in susceptibility already at concentrations below 2 mg/mL (Figure S3, Table S7-S8).

The MSC describes pharmacodynamically the lowest concentration where selection for resistance occurs [34]. To determine the MSC for
MTX, we constructed a fluorescently tagged pair of *E. coli* MG1655 strains to enable accurate separation between the two in mixed populations. In these backgrounds, we introduced TMPR, either through mutations (*folA*) using genome engineering or the pG06-VIM-1 plasmid. The isogenic TMPR and TMPS strain pairs were competed head-to-head by serial passage for 30 generations and the ratio of TMPR:TMPS was determined over time using flow cytometry. From this data the MSC was estimated (Tables S9-S10). Chromosomal *folA* mutations reduced fitness in *E. coli* MG1655 with 3.01% (+/- 0.71, SD) (Table S9) and displayed an MSC of 200 μg/mL (1/40 of the MIC of MTX) (Fig. 1). The MDR plasmid pG06-VIM-1 was selectively neutral (potentially slightly beneficial) displaying a 0.29% (+/- 0.24, SD) increase in fitness (Table S10). The latter estimates of relative fitness were close to the detection limit of the assay [34], and we conservatively estimated the MSC to be <25 μg/mL (less than 1/320 of the MIC of MTX) (Fig. 1). Taken together, our data strongly suggest that selection for TMPR occurs at MTX concentrations far below the estimated MTX MIC.

### 3.2. Sub-MICs of methotrexate promotes invasion of TMPβ determinants even when rare in *E. coli* populations

Exploring MTX-selective dynamics further, we asked if TMPβ determinants could invade the population at lower initial densities to exclude potential bias from the 1:1 ratio in the competition experiments. We started competition experiments from frequencies as low as 10⁻³ of the TMPβ strains, at concentrations slightly above the estimated MSC of MTX (400 μg/mL for *folA* mediated resistance and 75 μg/mL for pG06-VIM-1 mediated resistance) and followed the change in ratios over 30 generations of growth (Fig. 2, Table S11). Both chromosomal and plasmid mediated TMPβ determinants were able to invade, even when initially rare in their respective populations, strongly suggesting that the MTX selective effects are independent on initial frequencies of resistant and susceptible strains during competition experiments.

### 3.3. Methotrexate co-selects for resistance determinants on a multi-drug resistance plasmid

The *dfr*-genes represent a common TMPβ mechanism in *E. coli* and these genes are frequently located on mobile genetic elements such as integrons and plasmids. Given that MTX selects for *dfr*-mediated TMPβ, co-selection of other genetically linked resistance genes is likely. To show this, we used the MDR pG06-VIM-1 plasmid harboring *dfrA1* and *dfrA12* along with multiple resistance determinants including four aminoglycoside resistance genes and the *bla*VIM-1 carbapenemase gene conferring resistance to broad-spectrum β-lactams.
including carbapenems [24]. To assess the stability of pG06-VIM-1 in our strains competing in the presence of MTX, E. coli K56–2 harboring the plasmid pBAD30 (MP18–10) expression vector as well as strains with pBAD30 with different dfrA genes expressed under the inducible expression control by the pBAD promoter (MP18–11 and MP18–12). The detection limit of the assay is 64 µg/mL for TMP and 32 mg/mL for MTX. For both drugs, the MIC of E. coli DH5α expressing dfrA12 (MP18–12) exceeded the detection limit whereas the strain expressing dfrA1 (MP18–11) has the same MICs as the wt strain. Showing that MTX and TMP resistance conferred by the pG06-VIM-1 plasmid is caused by the dfrA12 gene.

Fig. 3. MTX and TMP MIC of E. coli DH5α expressing dfrA1 or dfrA12. The MTX (a) and TMP (b) MIC for the wild type (wt) E. coli DH5α (MP18–09) compared to the strain harboring the empty pBAD30 (MP18–10) expression vector as well as strains with pBAD30 with different dfrA genes expressed under the inducible expression control by the pBAD promoter (MP18–11 and MP18–12). The detection limit of the assay is 64 µg/mL for TMP and 32 mg/mL for MTX. For both drugs, the MIC of E. coli DH5α expressing dfrA12 (MP18–12) exceeded the detection limit whereas the strain expressing dfrA1 (MP18–11) has the same MICs as the wt strain. Showing that MTX and TMP resistance conferred by the pG06-VIM-1 plasmid is caused by the dfrA12 gene.

To verify that the TMPR determinants on the MDR pG06-VIM-1 plasmid is the primary mediators of MTX resistance and selection, both dfrA1 and dfrA12 were isolated from the plasmid (Table S2) and cloned onto an expression vector and the effects of the individual genes measured. Of the two genes, only dfrA12 was shown to give the same resistance pattern for TMP as well as MTX as the pG06-VIM-1 plasmid (Fig. 3), and the lack of detectable phenotype for dfrA1 (MP18–11) is likely due to a start codon frameshift mutation [24].

3.4. Methotrexate selects for de novo TMPR

We further examined whether exposure to MTX could lead to de novo TMPR evolution. We selected spontaneous mutants from overnight cultures with and without exposure to MTX, plated on selective agar at high MTX concentrations and tested for TMP cross-resistance (Figure S4, Table S12). E. coli K56–2 isolated at 16 and 32 mg/mL MTX (MP18–17 to MP18–28) displayed increased MICs of TMP close to or above the clinical breakpoint [38], clearly demonstrating selection for TMPR by MTX. DNA sequencing of the resistant isolates revealed two different mutations in the folA promoter, previously reported to result in TMPR [39], as well as a single mutation in the marR gene (Tables S12-S17).

Finally, we asked if exposure to sub-MICs of MTX close to the estimated MSCs would select for de novo TMPR mutations in a susceptible E. coli population. Starting from 1000 cells to minimize the probability of pre-existing mutants, we grew ten independent lineages of the E. coli K56–2 strain at 400 µg/mL MTX for 500 generations. The frequency of TMPR was determined every 50 generations. TMPR ascended in frequency in 2/10 lineages at different rates and time-points during the first 250 generations before they were outcompeted by a different set of mutants with reduced susceptibility to MTX and no cross-resistance to TMP (Fig. 4, Table S18). These experiments show that MTX exposure can select for de novo TMPR, both at high and sub-MIC concentrations. Arguably, the emergence of folA mutations in only 2 lineages is likely due to a larger mutational target within AcrAB-ToIC, resulting in reduced susceptibility towards MTX (and not TMP).

3.5. Pharmacokinetic approximations

To assess pharmacokinetic relevance, we attempted to estimate the MTX concentration range likely to be found in the intestine of patients undergoing MTX treatment. Limited information is available on gut MTX concentrations following intravenous administration during cancer treatment, as pointed out by others [2]. Pharmacokinetic data reveal that up to 90% of administered MTX is renally excreted [40] and we assume that the remaining ~10% of the dose constitutes the upper limit of the concentration range present in the human intestine. The lower limit is set to 2% of the dose based on the mean 3H labelled MTX concentrations measured in stool samples from nine patients receiving MTX intravenously [41]. From this, we set a 24 hour transition time in a total volume of 0.6 L [2] and calculated the dose (d) required to achieve MSC in the human intestine from:

\[
\frac{d}{0.6 \text{L}} x (0.1 \text{ or } 0.02) = \text{MSC}
\]

Estimated doses needed to reach intestinal MSCs assuming 2% and 10% fecal MTX concentrations were from 0.15 g to 0.75 g for plasmid-mediated TMPR and from 1.2 g to 6 g for chromosomal folA mutations. Thus, assuming close to 2m² body surface in growth-up patients [42] estimates of MSC for plasmid-mediated TMPR translates to dosing regimens from 75 to 375 mg/m² and from 0.6 to 3 g/m² for the chromosomal folA mutations. These approximations indicate that our MSC estimates are relevant for patients receiving high dose MTX treatment (1–12 g/m²) [43]. A recent study, also using a literature-based approach but with slight differences, estimates gut MTX concentrations following oral administration during treatment of rheumatoid arthritis [44]. Their data suggested MTX concentrations as high as 100 µg/mL are found in the lower intestine, suggesting that our estimated MSC for plasmid-mediated antibiotic resistance determinants (25 µg/mL) is well within this concentration range.

4. Discussion

Here we show that exposure to the cytotoxic drug MTX affects selection and evolution of TMPR determinants at clinically relevant concentrations. Notably, MTX can mediate selection of any antibiotic resistance determinant in E. coli when TMPR is co-localized on a mobile genetic element across a wide concentration gradient. Transferring the MDR plasmid pG06-VIM-1 into a K. pneumoniae strain resulted in reduced susceptibility towards MTX, suggesting that our findings are relevant beyond E. coli. Arguably, this potentially important side-effect of MTX treatment has been previously unrecognized, as studies on the effects of non-antibiotic drugs, including MTX, have either focused on bacterial growth inhibition or used drug concentrations around the MIC [2,45–47], with a few exceptions [4,48].

Using the approaches outlined here, including high resolution mixed culture competition experiments, allow determination of the true MTX selective window ranging from the MSC to the MIC [34].
Fig. 4. Evolution of TMP\textsuperscript{R} during MTX exposure for 500 generations. (a) Sub-MIC evolution experimental set-up. Ten biological replicates of K56--2 (MP06--01) were evolved for \textasciitilde 500 generations with 400 \( \mu \)g/mL MTX and three biological replicates without drug. All lineages were screened for TMP\textsuperscript{R} every 50 generations. After 500 generations all end-point populations were plated on 32 mg/mL MTX. All populations were able to grow at 32 mg/mL MTX, but not a single clone isolated conferred TMP\textsuperscript{R}, strongly suggesting that reduced susceptibility to MTX with no cross-resistance to TMP evolved in the endpoint populations. (b) Fractions of TMP\textsuperscript{R} folA mutants isolated every 50 generations from the lineages where these were detected. The detection limit of the assay was \( \sim 2 \times 10^{-9} \). Solid lines represent the two lineages where TMP\textsuperscript{R} emerged and ascended in frequency whereas dotted lines indicate spontaneous mutants.
This is particularly relevant for non-antibiotics for which bacteria display reduced susceptibility. In *E. coli*, MTX is a substrate for the AcrAB-ToIC efflux pump [17] and selective effects as those demonstrated here would not have been detected in classical susceptibility and/or growth assays in bacterial monocultures. This was recently supported in an *E. coli* chemical genetic screen where clear growth inhibitory effects of MTX, as well as for a range of other non-antibiotics, were only demonstrated in a tolC knock-out mutant (i.e. in a mutant lacking the intrinsic mechanism of resistance) [2].

Given that many cytotoxic drugs are structurally similar to antibiotics (e.g. doxorubicin/tetracyclines), or target similar key processes as the major antibiotic groups (e.g. DNA/protein synthesis) it is possible that cancer chemotherapy may lead to increased levels of antibiotic resistance in a vulnerable patient group that very often rely on efficient antibiotic treatment for survival. To acquire a deeper understanding of the evolutionary potential of novel, non-antibiotic drivers of antibiotic resistance the approaches presented here are essential. These approaches need to be combined with an improved understanding of the intestinal pharmaco-kinetics of MTX and other cytotoxic drugs, possible effects of co-administered drugs such as leucovorin mediated MTX rescue [49], and their interactions with the human microbiome. Such knowledge could allow identification of antibiotic + non-antibiotic drug combinations that should be avoided to preempt resistance evolution. This would be particularly relevant when considering repurposing cytotoxic drugs as antibiotics [50].

Taken together with recent studies showing that non-antibiotics can increase mutation rates [11,12] and promote horizontal gene transfer [48,51], the data presented here strengthens the evidence that non-antibiotic drugs can affect the evolution, selection, and spread of antibiotic resistance determinants. Our study is however not without limitations. Despite our pharmacokinetic considerations, which suggest that MTX selects and co-selects for antibiotic resistance determinants at clinically relevant concentrations, the lack of clinical data does limit our ability to conclude on the clinical and physiological significance of the results. Carefully designed in vivo experiments and/or clinical patient studies are important next steps to verify how MTX affect evolution, selection and spread of TMP resistance. One such approach could be a case study control comparing antibiotic resistance levels in patients that receive MTX compared to a group that does not, followed by microbiological and molecular analyses of bacteria and resistance determinants.

In this study we present data suggesting that MTX, a widely used drug in the treatment of several cancers as well as inflammatory diseases, may affect the evolution, selection and spread of antibiotic resistance. Moreover, we present an experimental frame-work where the true selective windows of non-antibacterial drugs can be determined. We argue that these approaches are critical to improve our understanding of non-antibacterial drugs as potential drivers of antibiotic resistance.

5. Contributors

The study was designed by JSG, EGAF, ØS and PJJ. Strain constructions were done by PT and JSG. Experiments were conducted by JSG, EGAF and CIMK. WGS analysis was done using a bioinformatic pipeline designed by JH. WGS data was verified by JH and JSG. Underlying data was verified by JSG and PJJ. Formal data analysis and data visualization was done by JSG. The first draft of the manuscript was written by JSG and revised by PJJ. All authors revised subsequent version and provided key edits to the manuscript. All authors read and approved the final version of the manuscript. Funding acquisition and resources were provided by PJJ and DIA.

Declaration of Competing Interest

The authors declare no competing interests.

Acknowledgments

We thank: Fredrik Sund, MD at The University Hospital North Norway for valuable input on medical aspects of MTX. Ass. Prof. Daniel Rozen, Leiden University for valuable discussions. Prof. Natasa Skalko-Basnet and Ass. Prof. Ann Mari Holsæter, UiT The Arctic University of Norway, for training in handling of cytostatic drugs.

Data sharing statement

All data used to draw the conclusions in this paper are provided in the paper and/or in the supplementary materials. WGS data are available at NCBI (BioProject PRJNA677979).

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2021.103742.

References

[1] Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet 2016;387(10014):176–87.
[2] Maer L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:623–8.
[3] Andersson DI, Hughes D. Selection and Transmission of Antibiotic-Resistant Bacteria. Microbiology Spectrum 2017;5(4).
[4] Gullberg E, Albrecht LM, Karlsson C, Sandgren L, Andersson DI, Selection of a Multidrug Resistance Plasmid by Sublethal Levels of Antibiotics and Heavy Metals. mBio 2014;5(5):e01918. 14.
[5] Klümper U, Dechevna A, Riber I, Brandt KK, Gulay A, Sørensen SJ, et al. Metal stressors consistently modulate bacterial conjugal plasmid uptake potential in a phylogenetically conserved manner. The ISME Journal 2017;11(1):152–65.
[6] Teillard A, Gandria S, Barter D, Morgan DJ, Laxminarayan R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. The Lancet Infectious Diseases 2015;15(12):1429–37.
[7] Danai PA, Moss M, Mannino DM, Martin GS. The Epidemiology of Sepsis in Patients With Malignancy. Chest 2006;129(6):1432–40.
[8] S-i Nakamura, Y Oda, Shimada T, Oki I, Sugimoto K. SOS-inducing activity of chemical carcinogens and mutagens in Salmonella typhimurium TA1535/psK1002: examination with 151 chemicals. Mutation Research Letters 1987;192(4):239–46.
[9] Foley GE, Mc CR, Binns VM, Snell EE, Guirard BM, Kidder GW, et al. A comparative study of the use of microorganisms in the screening of potential antimutagen agents. Annals of the New York Academy of Sciences 1958;76(3):38–41 413-3Bdiscussion.
[10] Papanicolaou LE, Gordon DI, Wesselingh SL, Rogers GB. Not Just Antibiotics: Is Cancer Chemotherapy Driving Antimicrobial Resistance? Trends in Microbiology 2018;26(5):393–400.
[11] Meuern A, Nerich V, Fagnoni-Legat C, Richard M, Mazel D, Adotey O, et al. Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs. Journal of Antimicrobial Chemotherapy 2019;74(6):1572–7.
[12] Hobson CA, Bonacorsi S, Hocquet D, Baruchel A, Fahd M, Storme T, et al. Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam. Scientific Reports 2020;19(1):589.
[13] Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The Pharmacology and Clinical Use of Methotrexate. New England Journal of Medicine 1983;309(18):1094–104.
[14] Mauldin RV, Carroll MJ, Lee AL. Dynamic dysfunction in dihydrofolate reductase: results from antifolate drug binding: modulation of dynamics within a structural state. Structure 2009;17(3):386–94.
[15] Bergström P, Holm S, Granqvist K, Henriksson R. Interaction between antibiotics and antineoplastic drugs on bacterial activity in vitro: Estramustine phosphate sensitizes pneumococci to amikacin. International Journal of Oncology 1994;4(2):435–9.
[16] Struwe MJ, Denis O, Rodríguez-Villalobos H, Microbiology of nosocomial infections: progress and challenges. Microbes and Infection 2004;6(11):1043–8.
[17] Kopysk SJ, Dyer JC, Knapp GS, Hu JC. Resistance to methotrexate due to AcrAB-TolC efflux pumps. Antimicrobial Agents and Chemotherapy 2002;46(11):3210–2.
[18] Reda H, Tomizawa J-i. Transducing fragments in generalized transduction by phage P1I. I. Molecular origin of the fragments. Journal of Molecular Biology 1965;14(1):85–109.
[19] Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in \textit{Escherichia coli} K-12 using PCR products. Proceedings of the National Academy of Sciences of the United States of America 2000;97(12):6640.

[20] Yu D, Ellis HM, Lee EC, Jenkins NA, Copeland NG. Court DL. An efficient recombination system for chromosome engineering in \textit{Escherichia coli}. Proceedings of the National Academy of Sciences of the United States of America 2000;97(11):5978–83.

[21] Sharan SK, Thomason LC, Kuznetsov SG. Court DL. Recombining: a homologous recombination-based method of genetic engineering. Nature protocols 2009;4(2):206–25.

[22] Nassi J, Knippel A, Andersson DL. Duplication-Insertion Recombining: a fast and scar-free method for efficient transfer of multiple mutations in bacteria. Nucleic acids research 2017;45(5):e33.

[23] Nyerges A, Czirók B, Nagy I, Bálint B, Bihari P, Lazár V, et al. A highly precise and portable genome engineering method allows comparison of mutational effects across bacterial species. Proceedings of the National Academy of Sciences of the United States of America 2016;113(9):2502.

[24] Di Luca MC, Samuelsen Ø, Starikova I, Kloos J, Haase SD, Johnsen PJ, et al. Low biological cost of carbapenemase-encoding plasmids following transfer from \textit{Klebsiella pneumoniae} to \textit{Escherichia coli}. Journal of Antimicrobial Chemotherapy 2016;72(1):85–9.

[25] Tu Q, Yin J, Fu J, Herrmann J, Li Y, Yin Y, et al. Room temperature electrocompetent bacterial cells improve DNA transformation and recombineering efficiency. Scientific Reports 2016;6:24848.

[26] Guzman LM, Belin D, Carson MJ, Beckwith J, Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. Journal of Bacteriology 1995;177(14):4121–30.

[27] Imamovic L, Ellabaa MMH, Dantas Machado AM, Citterio L, Wulff T, Molin S, et al. Drug-Driven Phenotypic Convergece Supports Rational Treatment Strategies of Chronic Infections. Cell 2018;172(1):321–34 e14.

[28] Munck C, Gumpert HK, Wallin AI, Wang HH, Sommer MOA. Use of Collateral Sensitivity Networks to Design Drug Combinations. The ISME Journal 2017;11(5):1168–78.

[29] Podnecky NL, Fredheim EGA, Kloos J, Hülter N, Johnsen PJ, et al. Low biological cost of carbapenemase-encoding plasmids following transfer from \textit{Klebsiella pneumoniae} to \textit{Escherichia coli}. Journal of Antimicrobial Chemotherapy 2016;72(1):85–9.

[30] Imamovic L, Sommer MOA. Use of Collateral Sensitivity Networks to Design Drug Cycling Protocols That Avoid Resistance Development. Science Translational Medicine 2013;5(204):204 ra132.

[31] Core Team R. \textit{R}: A language and environment for statistical computing. \textit{R} Foundation for Statistical Computing, Vienna, Austria.

[32] Thulin M. \textit{BAT}: an online tool for analysing growth curves. Available from http://www.mansthulin.se/bat/2019.

[33] Dykhuizen DE. Experimental Studies of Natural Selection in Bacteria. Annual Review of Ecology and Systematics 1990;21(1):373–98.

[34] Gullberg E, Cao S, Berg OG, Illvick C, Sandegren L, Hughes D, et al. Selection of Resistant Bacteria at Very Low Antibiotic Concentrations. PLOS Pathogens 2011;7(7):e1002158.

[35] Kahlmeter G. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens - interim report. The Journal of antimicrobial chemotherapy 2000;46(1):15–22 Supp 3:63–5.

[36] Coppel JN, Pletzer D, Brown AS, Van der Heijden J, Miton CM, Edgar RJ, et al. Mechanistic Understanding Enables the Rational Design of Saliicylanilide Combination Therapies for Gram-Negative Infections. mBio 2020;11(5):e02068. 20.

[37] Westhoff S, van Leeuwe TM, Qachach O, Zhang Z, van Wezel GP, Rozen DE. The evolution of no-cost resistance at sub-MIC concentrations of streptomycin in \textit{Streptomyces coelicolor}. The ISME Journal 2017;11(5):1168–78.

[38] The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters 2020 Version 10.0.

[39] Eliopoulos GM, Huvoinen P. Resistance to Trimethoprim-Sulfamethoxazole. Clinical Infectious Diseases 2001;32(11):1608–14.

[40] Seidenman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology 1993;35(4):409–12.

[41] Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Research 1965;25(7):1018–24.

[42] Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P, The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study. PLOS ONE 2010;5(1):e8933.

[43] Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 2016;21(12):1471–82.

[44] Nayak RK, Alexander M, Deshpande I, Stapleton-Gray K, Rimal B, Patterson AD, et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe 2021.

[45] Kruszewska H, Zareba T, Tysi S. Antimicrobial activity of selected non-antibiotics. Activity of methotrexate against \textit{Staphylococcus aureus} strains 2000:117–9.

[46] Moody MR, Morris MJ, Young VM, Moye LA, Schimpff SC, Wiernick PH. Effect of Two Cancer Chemotherapeutic Agents on the Antibacterial Activity of Three Anti-microbial Agents. Antimicrobial Agents and Chemotherapy 1978;14(4):737–42.

[47] Nyhlin A, Ljungberg B, Nilsson-Ehle I, Ödholm I. Bactericidal Effect of Combinations of Antibiotic and Antineoplastic Agents against \textit{Staphylococcus aureus} and \textit{Escherichia coli}. Chemotherapy 2002;48(2):71–7.

[48] Wang Y, Lu J, Mao L, Li J, Yuan Z, Bond PL, et al. Antiepileptic drug carbamazepine promotes horizontal transfer of plasmid-borne multi-antibiotic resistance genes within and across bacterial genera. The ISME Journal 2019;13(2):509–22.

[49] Van der Beek JN, Oosterom N, Pieters R, de Jonge R, van den Heuvel-Eibrink MM, et al. / EBioMedicine 2021;74(2021) 103742.